Business
CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry
New York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire ("CNW"), a m...
About this update from Infield Minerals Corp
[{"type":"text","content":"CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis IndustryNew York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire (\"CNW\"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"Biotech Market Banking on Big Cannabis Returns,\" discusses the innovation of today's biotech companies and the potential of the broader medicinal cannabis sector. To view the full publication, visit: https://www.cannabisnewswire.com/biotech-market-banking-big-cannabis-returns/InMed Pharmaceuticals, Inc.'s (CSE: IN) (OTCQB: IMLFF) market traction is based on the company's proprietary cannabinoid biosynthesis technology, one of three of its core assets and one which serves as the base for its development of its drug-development pipeline of novel therapeutics that leverage the pharmacological benefits of cannabinoids like CBD. As TheSeedInvestor.com asked in a recent article, could InMed be the \"next big thing in cannabis?\" (http://cnw.fm/JS9lv).To date, most CBD research and drug development has focused on the most easily isolated CBDs, but multiple curative opportunities are believed to be found in the other 90+ cannabinoids of the marijuana plant. InMed is the only known company with the ability to isolate and bio-identically manufacture all of the naturally occurring CBDs found in the cannabis sativa plant (http://cnw.fm/5BfmB). Conducted in-house, InMed's cost-effective biosynthesis process enhances the production, purification and quality control compared to other chemical manufacturing methods, such as chemical synthesis. InMed's ability to produce its own pharmaceutical grade, bio-identical CBDs also sets it apart from other companies that rely on outside cultivators for their product supply.About InMedInMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discov...